Why the study?
Does a (pro)renin-receptor-blocking decoy peptide prevent the development and progression of nephropathy in animal models of diabetes and hypertension?
Does a (pro)renin-receptor-blocking decoy peptide prevent the development and progression of nephropathy in animal models of diabetes and hypertension?
(Pro)renin-receptor blockade using a decoy peptide may offer a novel therapeutic approach for chronic kidney disease, particularly under low-renin conditions.
Supports (pro)renin-receptor blockade exploration in low-renin nephropathy models; leaves open human translation and high-renin efficacy.
Discovery of the (pro)renin receptor uncovered a novel function of renin/prorenin as the receptor ligands in addition to the enzyme and its precursor. The bindings of renin and prorenin to the (pro)renin receptor trigger two major pathways: the angiotensin II-dependent pathway as a result of the enzymatic activation of renin/prorenin and the angiotensin II-independent intracellular pathway involving hypertrophic, hyperplastic, and profibrotic signals. A specific blocker of the receptor was discovered through identification of the amino acid sequence of prorenin prosegment that binds to the receptor and leads to non-proteolytic conversion of prorenin to its active form. A peptide containing this sequence was found to block the binding of prorenin to its receptor. Its infusion in animal models of diabetes and low-renin hypertension significantly inhibited the development and progression of nephropathy, but (pro)renin receptor blockade had no benefit in the clipped kidney of 2K1C rats or rat models of high-renin hypertension. Since renin is still active without a (pro)renin receptor, (pro)renin-receptor blockade elicits a maximum benefit under low-renin conditions. Thus, (pro)renin-receptor blockade can be a useful therapy for chronic kidney disease with low renin levels in the plasma.
No takes yet. Share an insight, caveat, or question.
Ichihara et al. (2009) studied this question.